Esperion's LDL-Cholesterol Drug To Follow PCSK9 Inhibitor Approval Pathway
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says FDA confirmed that cardiovascular outcomes data will not be required for initial submission of ETC-1002 in patients with familial hypercholesterolemia and atherosclerotic CV disease; Esperion expects to start Phase III development by the end of 2015.